Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase

被引:144
作者
He, YP
Nakao, HH
Tan, SL
Polyak, PJ
Neddermann, P
Vijaysri, S
Jacobs, BL
Katze, MG
机构
[1] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA
[2] Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA
[3] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[4] Arizona State Univ, Dept Microbiol, Tempe, AZ 85287 USA
[5] Arizona State Univ, Grad Degree Program Mol & Cellular Biol, Tempe, AZ 85287 USA
[6] Ist Ric Biol Mol P Angeletti, Rome, Italy
关键词
D O I
10.1128/JVI.76.18.9207-9217.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C virus (HCV) sets up a persistent infection in patients that likely involves a complex virus-host interaction. We previously found that the HCV nonstructural 5A (NS5A) protein interacts with growth factor receptor-binding protein 2 (Grb2) adaptor protein and inhibits the activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) by epidermal growth factor (EGF). In the present study, we extended this analysis and investigated the specificity of the Grb2-NS5A interaction and whether the subversion of mitogenic signaling involves additional pathways. NS5A containing mutations within the C-terminal proline-rich motif neither bound Grb2 nor inhibited ERK1/2 activation by EGF, demonstrating that NS5A-Grb2 binding and downstream effects were due to direct interactions. Interestingly, NS5A could also form a complex with the Grb2-associated binder I (Gab1) protein in an EGF treatment-dependent manner. However, the NS5A-Gab1 association, which appeared indirect, was not mediated by direct NS5A-Grb2 interaction but was likely dependent on direct NS5A interaction with the p85 subunit of phosphatidylinositol 3-kinase (PI3K). The in vivo association of NS5A with p85 PI3K required the N-terminal, but not the C-terminal, region of NS5A. The downstream effects of the NS5A-p85 PI3K interaction included increased tyrosine phosphorylation of p85 PI3K in response to EGF. Consistent with this observation and the antiapoptotic properties of NS5A, we also detected enhanced tyrosine phosphorylation of the downstream AKT protein kinase and increased serine phosphorylation of BAD, a proapoptotic factor and an AKT substrate, in the presence of NS5A. These results collectively suggest a model in which NS5A interacts with Grb2 to inhibit mitogenic signaling while simultaneously promoting the PI3K-AKT cell survival pathway by interaction with p85 PI3K, which may represent a crucial step in HCV persistence and pathogenesis.
引用
收藏
页码:9207 / 9217
页数:11
相关论文
共 58 条
[1]   Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins [J].
Aizaki, H ;
Saito, S ;
Ogino, T ;
Miyajima, N ;
Harada, T ;
Matsuura, Y ;
Miyamura, T ;
Kohase, M .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (12) :1111-1120
[2]   Efficient initiation of HCV RNA replication in cell culture [J].
Blight, KJ ;
Kolykhalov, AA ;
Rice, CM .
SCIENCE, 2000, 290 (5498) :1972-1974
[3]   Extracellular HIV-1 Tat protein activates phosphatidylinositol 3- and Akt/PKB kinases in CD4(+) T lymphoblastoid Jurkat cells [J].
Borgatti, P ;
Zauli, G ;
Colamussi, ML ;
Gibellini, D ;
Previati, M ;
Cantley, LL ;
Capitani, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (11) :2805-2811
[4]   VACCINIA VIRUS ENCODES A POLYPEPTIDE HOMOLOGOUS TO EPIDERMAL GROWTH-FACTOR AND TRANSFORMING GROWTH-FACTOR [J].
BROWN, JP ;
TWARDZIK, DR ;
MARQUARDT, H ;
TODARO, GJ .
NATURE, 1985, 313 (6002) :491-492
[5]  
Cantrell DA, 2001, J CELL SCI, V114, P1439
[6]  
Coffer PJ, 1998, BIOCHEM J, V335, P1
[7]   Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen [J].
Dahl, J ;
Jurczak, A ;
Cheng, LA ;
Baker, DC ;
Benjamin, TL .
JOURNAL OF VIROLOGY, 1998, 72 (04) :3221-3226
[8]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[9]  
Di Bisceglie Adrian M., 1998, Hepatology, V28, P1161, DOI 10.1002/hep.510280436
[10]   Hepatitis C [J].
Di Bisceglie, AM .
LANCET, 1998, 351 (9099) :351-355